NextCure, Inc. (NXTC)

1.6600 +0.0900 (+5.66%) As of 10:19AM EDT. Market open.

NextCure, Inc.

9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
United States
240 399 4900
https://www.nextcure.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 82

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael S. Richman MSBA	Co-Founder, CEO, President & Director	713.95k	N/A	1961
Dr. Solomon Langermann Ph.D.	Chief Scientific Officer	538.62k	N/A	1960
Dr. Han Myint FACP, M.D.	Chief Medical Officer	554.46k	N/A	1953
Mr. Steven P. Cobourn CPA	Chief Financial Officer	313.25k	N/A	1963
Dr. Timothy Mayer Ph.D.	Chief Operating Officer	N/A	N/A	1965
Mr. Kevin G. Shaw	General Counsel	N/A	N/A	1974
Ms. Stacy Rollinger	Vice President of Human Resources	N/A	N/A	N/A
Mr. Sourav Kundu Ph.D.	Senior Vice President of Development & Manufacturing	N/A	N/A	1960
Dr. Sebastien Maloveste	Senior Vice President of Business Development	N/A	N/A	N/A
Dr. Udayan Guha M.D., Ph.D.	Senior Vice President of Clinical & Translational Development	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Corporate governance

NextCure, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.